PENN Researchers Find That Pet Imaging Sheds More Light On Complex, Microscopic Cancers

September 10, 1998

PET Scans Reveal Malignant Areas Where Other Techniques Cannot

(Philadelphia, PA) -- Managing cancer is challenging for physicians in and of itself, but with certain types of cancer, diagnosis is difficult as well. In cancers based in unusual locations, such as in the lining of the lung (mesothelioma) or in the lymph nodes, conventional imaging technology cannot detect malignant cells or differentiate them from benign, or non-cancerous, ones. In a multi- disciplinary study evaluating malignant mesothelioma at the University of Pennsylvania Medical Center, researchers have shown the potential advantages of using positron emission tomography (PET) over structural imaging, including conventional X-Ray, magnetic resonance imaging (MRI), and computerized tomography (CT). These findings appear in the September issue of Chest, the official journal of the American College of Chest Physicians.

In contrast to structural radiologic techniques, PET technology is based on cellular metabolism -- the chemical reaction that drives the human body. PET imaging is non-invasive and is obtained as patients lie prone in a tube-like structure while detectors take readings of the body. A tracer agent is injected prior to the scan and binds to the organ or diseased sites. As a result, the tumorous area is highlighted with bright points of light on a PET computer screen, depicting clusters of malignant cells. PET imaging is sensitive enough to detect cancer cells in lymph nodes smaller than one centimeter. Other imaging technology may not recognize these microscopic tumor cells until they were larger -- perhaps two or more months later. Moreover, PET can provide images soon after treatment to show physicians whether the therapy is effective or not.

"Consider the benefits of using PET imaging with life-threatening, microscopic cancers," says Abass Alavi, MD, co-investigator of the study and Chief of the Nuclear Medicine division at Penn. "This technique can detect tumors well before structural scans are able to identify them, can accurately determine the extent and exact area of the body where tumorous cells are active, and can show treatment response soon after it is administered."

In this study, a minimally-radioactive tracer agent called 2-Deoxy- 2(18F)fluoro-D-glucose, or FDG, was administered in 28 patients before PET scanning. FDG is sensitive to the increased glucose metabolism observed in malignant tumor cells, generating points of white light on PET scans to represent areas of active tumor. The results of PET imaging were compared to those of CT scans, video-assisted thoracoscopy (examination of the chest cavity with an endoscope), and/or surgical biopsies. The FDG-PET images differentiated malignant and benign disease, achieving ninety-one percent (91%) sensitivity in detecting the tumors and one-hundred percent (100%) specificity between cancerous and non-cancerous cells in these patients. FDG-PET images provided excellent delineation of the active tumor sites. Metabolic lymph node activity was found in the FDG-PET images of 12 patients, nine of which appeared negative on CT scans.

"PET scans recognize malignant tumors that may go unnoticed by X-Ray, MRI, or CT scans," explains Daniel Sterman, MD, co-investigator and director of Penn's Interventional Pulmonary Program. "This technology allows us to make more precise assessments without the use of contrast dyes or invasive instruments."

Mesothelioma is primarily associated with exposure to asbestos and is characterized by the appearance of tumorous cells in the lining of the lung and chest cavity. The incidence of malignant mesothelioma is expected to rise until the year 2000, and will remain substantial for the next three decades. Mesothelioma cases are on the rise in women and those with no asbestos exposure as well. In difficult cases of microscopic cancers such as those in the lining of the lung or in the lymph nodes, conventional imaging cannot clearly establish malignancy. PET imaging can pinpoint the areas of disease activity, as well as evaluate response to treatment, to provide crucial information for disease management.

Editor's notes:
Dr. Alavi can be reached directly by calling (215) 662-3069;
Dr. Sterman can be reached directly by calling (215) 614-0984.
-end-


University of Pennsylvania School of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.